We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Immunoassay Used to Diagnose Acute Leukemia.

By LabMedica International staff writers
Posted on 05 Oct 2010
An immunofluorescence (IF) assay, using monoclonal antibodies, has been evaluated for the diagnosis of acute promyelocytic leukemia (APL), which is considered a medical emergency.

APL is a distinct subtype of acute myeloid leukemia (AML) characterized by a reciprocal translocation, and a high incidence of life-threatening coagulopathy. More...
As reverse transcription-polymerase chain reaction (RT-PCR) for the promyelocytic leukemia (PML) - retinoic acid receptor (RAR) alpha fusion oncoprotein is time consuming, there is a need for a rapid and accurate diagnostic test for APL.

A study was carried out at the All India Institute of Medical Sciences, (New Delhi, India), to evaluates the role of the monoclonal antibody, PG-M3, using immunofluorescence (IF) in the early diagnosis of APL. PG-M3 antibodies are specifically directed against a peptide sequence located in the amino-terminal region of the human PML protein. Thirty-six new untreated APL cases diagnosed with RT-PCR for PML-RAR alpha as the gold standard and 38 non-APL controls (28 non-APL AMLs and 10 non-leukemia samples) were evaluated by routine morphology and cytochemistry, RT-PCR, and IF using PG-M3 monoclonal antibody. The median age of APL patients was 35 years (range 9–75 years) and included 19 men and 17 women.

The IF assay, using the PG-M3 antibodies, takes two hours to perform. Of the 36 APL cases, 34 (94.4 %) showed a microgranular pattern of immunofluorescence (IF) and two cases (5.6%) showed speckled pattern indicating possible false negatives. Of 28 non-APL AML controls, 26 (92.9%) showed a speckled pattern and two (7.1%) cases showed microgranular pattern indicating false positives. IF was significantly superior compared with morphology alone for the diagnosis of APL. All 10 non-leukemic controls were correctly identified as negative for APL on both morphology and IF (speckled). There were no cases or controls, which could not be evaluated by IF. The study was published online on August 4, 2010 in the European Journal of Clinical Investigation.

The authors concluded that, PG-M3 antibodies could be used as a rapid, cheap, sensitive, and specific method to identify APL. It can be a useful adjunct for diagnosis of APL especially if facilities for RT-PCR are not available, particularly in resource-limited settings.

Related Links:

All India Institute of Medical Sciences




New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.